Tanabe Pharma Corp v. Cipla USA Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: Tanabe Pharma Corporation (Japan)
  • Defendant: Cipla USA, Inc. (New Jersey) and Cipla Limited (India)
  • Plaintiff's Counsel: FBT Gibbons LLP
• Case Identification: 2:26-cv-01734, D.N.J., Filed 02/20/2026
• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because Defendant Cipla USA, Inc. is incorporated and has an established place of business in New Jersey. Plaintiff further alleges that both defendants have previously consented to venue in the district through prior litigation.
• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking to market a generic version of Plaintiff's RADICAVA ORS® product, constitutes an act of patent infringement.
• Technical Context: The dispute centers on a pharmaceutical formulation of edaravone, an approved treatment for amyotrophic lateral sclerosis (ALS), and a patented method for its oral administration that manages food-related effects on drug absorption.
• Key Procedural History: The litigation was triggered by Defendants' submission of ANDA No. 218428 with a Paragraph IV certification, asserting that the patent-in-suit is invalid, unenforceable, or will not be infringed by the proposed generic product. The complaint notes that Plaintiff previously filed a separate action against the same defendants concerning a related patent.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,478,611 - "Pharmaceutical composition for oral administration of edaravone and method of administering same"

The patent-in-suit is U.S. Patent No. 12,478,611, issued November 25, 2025 (the "'611 Patent").

The Invention Explained

• Problem Addressed: The patent addresses the challenge that the pharmacokinetics of orally administered edaravone-a drug used to treat oxidative stress diseases like amyotrophic lateral sclerosis (ALS)-are significantly affected by the consumption of food Compl. ¶¶3, 8 '611 Patent, col. 33:57-63 This "food effect" can lead to inconsistent drug absorption and potentially reduced therapeutic efficacy, a critical issue for patients with a progressive disease like ALS '611 Patent, col. 1:46-54
• The Patented Solution: The invention is a method of administration that mitigates this food effect. It specifies precise time intervals between a patient's meal and the drug's administration, tailored to the type of meal consumed (e.g., high-fat, standard, or light) '611 Patent, abstract By following this timed dosing regimen, the method claims to achieve drug absorption levels (specifically, Cmax and AUC) that are equivalent to those achieved when the drug is taken in a fasted state, thereby ensuring consistent bioavailability '611 Patent, col. 2:1-22
• Technical Importance: This method provides a predictable oral dosing regimen, which reduces the burden on ALS patients and their caregivers compared to intravenous administration and ensures the drug's therapeutic effect is not compromised by a patient's diet Compl. ¶¶8-9

Key Claims at a Glance

• The complaint asserts infringement of one or more claims, including at least independent Claim 1 Compl. ¶44
• The essential elements of independent Claim 1 include:
  • A method for treating amyotrophic lateral sclerosis.
  • Orally or intragastrically administering a liquid pharmaceutical composition containing edaravone at a dose of 90 to 120 mg.
  • Administering the composition after a "first time interval" following a meal.
  • This interval must be sufficient to achieve "the same pharmacokinetics (including Cmax and AUC)" as administration under a fasted condition.
  • The specific interval is defined by the meal type: 8 hours for a high-fat meal, 4 hours for a standard meal, and 2 hours for a light meal.
• The complaint's reference to "one or more claims" suggests the right to assert dependent claims is preserved Compl. ¶44

III. The Accused Instrumentality

Product Identification

Defendants' proposed generic edaravone oral suspension, for which approval is sought under ANDA No. 218428 Compl. ¶¶18, 36

Functionality and Market Context

• The accused product is an oral suspension of edaravone proposed at a dose concentration of 105 mg/5 ml Compl. ¶36
• It is intended to be a generic copy of Plaintiff's branded product, RADICAVA ORS®, and identifies RADICAVA ORS® as its reference listed drug ("RLD") in its FDA submission Compl. ¶¶37-38 The complaint alleges that upon approval, Defendants will commercially manufacture, market, and sell this product for the treatment of ALS Compl. ¶¶24, 46

IV. Analysis of Infringement Allegations

The complaint does not provide a detailed, element-by-element infringement analysis or a claim chart. The central allegation is that the very act of submitting ANDA No. 218428, which seeks FDA approval to market a generic drug for a use claimed in the '611 Patent before its expiration, constitutes a statutory act of infringement under 35 U.S.C. § 271(e)(2) Compl. ¶45 The underlying infringement theory in such a case is that the proposed product's labeling will instruct or encourage physicians and patients to use the drug in a manner that practices the patented method.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Scope Questions: The dispute may turn on whether Defendants' proposed product label will necessarily instruct administration in a way that falls within the specific time-interval limitations of Claim 1. A key question is whether Defendants can successfully "carve out" the patented method of use from their label to avoid infringement while still obtaining approval for treating ALS.
  • Technical Questions: A central issue will be whether administration according to Defendants' proposed instructions for use would, in fact, achieve "the same pharmacokinetics" as administration in a fasted state, as required by the claims.

V. Key Claim Terms for Construction

• The Term: "the same pharmacokinetics"
• Context and Importance: This term is the core functional requirement of the claimed method. The entire purpose of the specified time intervals is to achieve this result. The definition of "the same" will be critical to determining infringement, as it sets the standard that the accused method of administration must meet. Practitioners may focus on this term because its interpretation-whether it requires near-perfect identity or allows for statistical equivalence-could determine the outcome of the case.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent specification provides a potential safe harbor by linking the term to a well-understood regulatory standard. It states that "the same pharmacokinetics" can mean that a "least squares mean ratio and its 90% confidence interval are in the range of 0.8 to 1.25," which is a common criterion for bioequivalence '611 Patent, col. 6:15-18 This language may support a construction where "the same" means "statistically bioequivalent."
  • Evidence for a Narrower Interpretation: The claim language uses the definitive phrase "the same," not "bioequivalent" or "statistically similar." The specification also uses phrases like "completely identical or in a range not significantly different" and "no significant change" '611 Patent, col. 5:4-6 '611 Patent, col. 6:12 This language could support a narrower construction requiring a higher degree of similarity than the 0.8-1.25 bioequivalence range.

VI. Other Allegations

• Indirect Infringement: The complaint seeks a declaratory judgment that if Defendants commercially launch their product, they will induce or contribute to infringement Compl. ¶50 The factual basis for this allegation is the presumed marketing of the generic product with a label and instructions that will inevitably cause patients and physicians to perform the patented method.
• Willful Infringement: The complaint does not use the word "willful," but it alleges that Defendants had "actual and constructive notice" of the '611 Patent before filing their ANDA Compl. ¶48 In the prayer for relief, Plaintiff requests a declaration that the case is "exceptional" and an award of attorneys' fees under 35 U.S.C. § 285, which is often predicated on findings of willful infringement or other litigation misconduct Compl., Prayer ¶E

VII. Analyst's Conclusion: Key Questions for the Case

This dispute appears to center on the intersection of patent law and FDA regulations. The key questions for the court will likely be:

• A core issue will be one of definitional scope: How will the court construe the term "the same pharmacokinetics"? Will this be interpreted as requiring near-perfect identity, or will it be defined by the more flexible statistical bioequivalence standards referenced in the patent's specification?
• A key question of induced infringement will be central to the case: What will the Defendants' proposed product label instruct regarding administration with respect to meals? Can Defendants successfully market a generic edaravone product for treating ALS without inevitably instructing or encouraging patients to use it in a way that infringes the specific meal-timing methods claimed in the '611 Patent?